GB590 Corporate Social Responsibility Prof. Ray Kalinski By Willette Marchany Rivera December 13, 2010
Introduction: Industry Overview Objectives Industry Audit ◦ Social ◦ Environmental ◦ Economic Industry Stakeholders Analysis ◦ Stockholders ◦ Consumers ◦ Employees Conclusion References
Ethical drugs for human consumption at ex-factory prices: ◦ Research ◦ Development ◦ Manufacture ◦ Marketing 5.3% industry market value growth in 2009 translates to $1,071.7 billion Expected market value increase of 30.9% from 2009 to 2014 Pharmaceuticals is the largest segment: 75.7% of the industry's total value. Americas accounts for 50.5% of the industry value
Track important development of social, environmental, and economic issues affecting the pharmaceutical industry Explore the positions and perspectives of the various stakeholders with regards to the social, environmental, and economic matters affecting the industry
Use of natural/alternative medicine and “green” trends Safety concerns about drugs and their secondary effects Poor countries where the indigent can’t pay to acquire medicines Treating symptoms instead of finding a cure for the disease or condition Marketing methods and direct to consumer advertising. Industry Audit
Strict environmental laws in United States and Europe Fuel consumption and air pollution Climate change ◦ Volatile Organic Compounds (VOC) ◦ Ozone Depleting Compounds (ODC) Water usage, consumption and treatment Energy efficiency Waste and efficient packaging Industry Audit
Research & development costs High price of pharmaceutical drugs International trade: Safety regulations vary between countries pose barriers to entry Tax increases and changes in fiscal exemptions Freight costs: Fuel prices and Transportation Security Agency regulations Industry Audit
Profits Drug patents Ethical behavior SuppliersSocietyEnvironment Employees Medical Professionals Patients Stockholders &. Investors Industry Stakeholders
Consumer’s rights ◦ Receive accurate information Human rights ◦ The right to health SuppliersSocietyEnvironment Employees Medical Professionals Patients Stockholders &. Investors Industry Stakeholders
Physicians & Pharmaceutical Medicine Rewarding ethical behavior Best companies to work for SuppliersSocietyEnvironment Employees Medical Professionals Patients Stockholders &. Investors Industry Stakeholders
Pharmaceutical industry is strong and profitable Several ethical concerns regarding drug safety, efficiency and sustainability
Alternative Medicine Industry Overview. (2009, April 27). Themedica: Global Health Marketplace. Retrieved December 13, 2010 from Kitsis, E. A. (2009). Rx for the Pharmaceutical Industry: Call Your Doctors. Hastings Center Report, 39(4), Retrieved from EBSCOhost. Lawrence, A. T. (2011). Merck, the FDA, and the Vioxx recall. In Lawrence, A. T. Weber, J., Business and Society: Stakeholders, Ethics, Public Policy (pp ). New York: McGraw-Hill. Luthra, R. (2006, November). Health-care patents and interests of patients. Bulletin of the World Health Organization, 84 (11). (pp.919) Springfield, MA: Woman’s Health Education Center Melia, M. (2007, November 26). Plantas farmacéuticas abandonan Puerto Rico. La Voz. Retrieved December 13, 2010 from Muhairwe, A. (2008). Harmonization of drug regulation in East Africa: the way forward. Presentations from 13th International Conference of Drug Regulatory Authorities (ICDRA). World Health Organization. Retrieved December 13,2010 from _legislation/icdra/2_Uganda_HarmonisationDrugRegulation-EastAfrica.pdf Pharmaceuticals, Biotechnology & Life Sciences Industry Profile: Global. (2010). Pharmaceuticals, Biotechnology & Life Sciences Industry Profile: Global, 1. Retrieved from EBSCOhost. Slowik, E. (2010). Newton: Big pharma seeks partners, not purchases. Grand Rapids Business Journal, 28(41), 3. Retrieved from EBSCOhost. The right to the highest attainable standard of health: General Comment No. 14. (2000). United Nations Economic and Social Council. Retrieved December 12, 2010 from